Efficacy and safety of the ALK inhibitor alectinib in ALK+ non-small-cell lung cancer (NSCLC) patients who have failed prior crizotinib: An open-label, single-arm, global phase 2 study (NP28673).
Year: 2015
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Sai-Hong Ignatius Ou, Jin Seok Ahn, Luigi De Petris, Ramaswamy Govindan, James Chih-Hsin Yang, Brett Gordon Maxwell Hughes, Hervé Lena, Denis Moro-Sibilot, Alessandra Bearz, Santiago Viteri Ramirez, Tarek Mekhail, Alexander I. Spira, Ali Hassan Zeaiter, Walter Bordogna, Bogdana Balas, Sophie Golding, Peter N. Morcos, Dong-Wan Kim
Institutions: University of California, Irvine, UC Irvine Chao Family Comprehensive Cancer Center, Samsung Medical Center, Karolinska University Hospital, Washington University in St. Louis, National Taiwan University, Prince Charles Hospital, Hôpital Pontchaillou, Centre Hospitalier Universitaire de Rennes, Inserm, Hôpital Albert Michallon, Hospital Universitario Dexeus, Florida Hospital Cancer Institute, Virginia Cancer Specialists, F. Hoffmann-La Roche AG, Seoul National University Hospital
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2266979115